A MODERN APPROACH TO THE TREATMENT OF HDV INFECTION
Keywords:
Keywords: treatment hepatitis D, hepatitis B, bulevirtide, interferon-alfaAbstract
Abstract: HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by the EMA. BLV is a synthetic N-acylated pre-S1 lipopeptide that blocks the binding of HBsAg-enveloped particles to the sodium taurocholate co-transporting polypeptide (NTCP), which is the cell entry receptor for both HBV and HDV. In this review, we discuss the available data from the ongoing clinical trials and from “real world series”. Clinical trials and real-world experiences demonstrated that BLV 2 mg administered for 24 or 48 weeks as monotherapy or combined with pegIFNα reduces HDV viremia and normalizes ALT levels in a large proportion of patients. The combination of BLV and pegIFNα shows a synergistic on-treatment effect compared with either one of the monotherapies.
References
M. Rizzetto, S. Hamid. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal Liver Int, 41 (2021), pp. 16-19
B.L. Da, F. Rahman, W.C. Lai, D.E. Kleiner, T. Heller, C. Koh. Risk factors for Delta hepatitis in a North American cohort: who should be screened? Am J Gastroenterol, 116 (2021), pp. 206-209
D. Alfaiate, S. Clément, D. Gomes, N. Goossens, F. Negro. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol, 73 (2020), pp. 533-539
F. Negro. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med, 4 (2014), p. a021550
C. Koh, B.L. Da, J.S. Glenn. HBV/HDV coinfection: a challenge for therapeutics. Clin Liver Dis, 23 (2019), pp. 557-572
Modern Approaches to Treatment of Chronic Giardiasis. AA Elmuradova, AS Djalilova - Central Asian Journal of Medical and Natural Science, 2022
Вклад Абу али ибн Сино в развитие фитотерапии. АА Элмурадова, ДС Косимова, НШ Шадыева - Новый день в медицине, 2020
Viral Hepatitis Delta: An Underestimated Threat. AA Elmurodova - Texas Journal of Medical Science, 2023
Specific Features of the Hemostatic System in Covid-19. AA Elmurodova - Central Asian Journal of Medical and Natural Science, 2022
Elmurodova , A. . (2023). ROLE OF CYTOKINES IN THE DEVELOPMENT OF LIVER CIRRHOSIS, WHICH DEVELOPED AS A RESULT OF CHRONIC VIRAL HEPATITIS D. Евразийский журнал медицинских и естественных наук, 3(11), 217–221. извлечено от https://in-academy.uz/index.php/EJMNS/article/view/23842
Significance of Clinical Symptoms in Assessing the Severity and Prognosis of the Course of Crimean-Congo Hemorrhagic Fever. AA Elmurodova - Central Asian Journal of Medical and Natural Science, 2021
Obloqulov, A. R., Oblokulova, Z. I., Elmurodova, A. A., & Farmanova, M. A. (2020). Virologic response in the treatment of infection with antiviral drugs. World Journal of Pharmaceutical Research, 9(9), 87-92.
Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 3(4), 19–25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506
Oblokulov A.R., M.I.Mukhammadieva.(2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis//Academicia Globe: Indersciense Research.-2022.- P. 210-216.
Облоқулов, А., & Муҳаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИИ. Журнал вестник врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016
